An Observational Study of Patients With HER2-Positive Metastatic or Locally Advanced Breast Cancer Treated With Herceptin (Trastuzumab) in 1st Line and Without Progression For 3 Years
Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Hoffmann-La Roche
Age
18–any
Sex
FEMALE
Healthy volunteers
Not accepted
You may be eligible if
Female patients, \>/= 18 years of age
HER2-positive metastatic breast cancer or locally advanced breast cancer
Systemic treatment included Herceptin as 1st line therapy
Without progression for at least 3 years after the beginning of Herceptin treatment
Alive or not alive and treated or not treated with Herceptin at the time of inclusion
You may not be if
Disease progression \<3 years after beginning 1st-line therapy with Herceptin
Clareo Health | An Observational Study of Patients With HER2-Positive Metastatic or Locally Advanced Breast Cancer Treated With Herceptin (Trastuzumab) in 1st Line and Without Progression For 3 Years
